Jennifer Hinkel Joins Cizzle Bio as Senior Consultant, Economics & Commercialization
Cizzle Bio is pleased to welcome Jennifer Hinkel, MSc, as our Senior Consultant, Economics & Commercialization. With extensive expertise in health economics, market access, and oncology-focused commercialization strategies, Jennifer brings valuable insights that will help drive the adoption and impact of Cizzle Bio’s biomarker-based cancer diagnostics.
A Leader in Market Access & Health Economics
With over 15 years of experience in health economics and outcomes research (HEOR), real-world evidence (RWE), pricing, and commercialization, Jennifer has worked with leading biopharma and medtech companies to navigate complex regulatory and payer landscapes.
Her career includes key leadership roles at:
Genentech, where she played a pivotal role in oncology market access and pricing strategies.
Caris Life Sciences, focusing on biomarker-driven precision medicine.
McGivney Global Advisors, where she advised global healthcare companies on commercial strategy and reimbursement models.
Jennifer’s expertise in oncology diagnostics and global health policy will be instrumental in shaping Cizzle Bio’s commercialization and market expansion efforts.
Bridging Innovation, Policy & Patient Access
In addition to her industry leadership, Jennifer holds an MSc in International Health Policy from the London School of Economics and is currently pursuing a DPhil in Evidence-Based Health Care at the University of Oxford, with a focus on cancer outcomes.
As a cancer survivor and patient advocate, she is deeply committed to ensuring that innovative healthcare solutions reach the patients who need them most. Her unique perspective—combining scientific rigor, policy expertise, and real-world patient insights—aligns with Cizzle Bio’s mission to improve early cancer detection and accessibility.
Driving Cizzle Bio’s Commercial Strategy
Jennifer’s expertise will help Cizzle Bio strengthen its commercialization efforts by:
Developing market access strategies to ensure widespread adoption of biomarker-based diagnostics.
Navigating regulatory and payer landscapes for international expansion.
Leveraging real-world evidence (RWE) and health economics to demonstrate the value of Cizzle Bio’s technology.
Her insights will be crucial in supporting the successful rollout of Cizzle Bio’s lung and gastrointestinal cancer diagnostics to both clinical and commercial markets.
Looking Ahead
Jennifer joins Cizzle Bio at a pivotal moment, as we continue to expand our presence in early cancer detection and precision medicine. Her expertise in health economics, reimbursement, and market access will be instrumental in accelerating the impact of our diagnostic solutions.
We are thrilled to have Jennifer Hinkel on board and look forward to the transformative advancements her leadership will bring.
Please join us in welcoming Jennifer to the Cizzle Bio team!
